NewAmsterdam Pharma Company N.V. (NAMS) shares surged 5.9% to $32.48 on high volume, up 13.6% in the past four weeks. Investor optimism is on the rise due to the potential of obicetrapib, being studied as a treatment to lower LDL-C in patients with cardiovascular disease or hypercholesterolemia.

The company is expected to report a quarterly loss of $0.41 per share with revenues of $2.35 million, down 91.9% from last year. Analysts emphasize the importance of earnings estimate revisions in stock price movements, urging caution for NAMS investors to monitor future trends closely.

Stevanato Group (STVN) closed 5.6% lower at $24.53, returning 7.6% in the past month. The consensus EPS estimate for STVN is $0.15, up 15.4% from last year, with a Zacks Rank of #2 (Buy). This presents a potential opportunity for investors seeking growth in the medical industry.

Read more at Nasdaq: NewAmsterdam Pharma Company N.V. (NAMS) Soars 5.9%: Is Further Upside Left in the Stock?